Assay Can ID M. tuberculosis Resistance Mutations

Share this content:
Assay Can ID <i>M. tuberculosis</i> Resistance Mutations
Assay Can ID M. tuberculosis Resistance Mutations

THURSDAY, Sept. 14, 2017 (HealthDay News) -- An automated molecular assay can detect Mycobacterium tuberculosis with resistance to drugs directly from sputum specimens, according to a study published in the Sept. 14 issue of the New England Journal of Medicine.

Yingda L. Xie, M.D., from the National Institutes of Health in Bethesda, Md., and colleagues compared the investigational assay against phenotypic drug-susceptibility testing and DNA sequencing among adults with symptoms of tuberculosis. The authors performed the Xpert MTB/RIF assay and sputum culture.

The researchers found that the sensitivities of the investigational assay for detecting resistance were 83.3 percent for isoniazid, 88.4 percent for ofloxacin, 87.6 percent for moxifloxacin, 71.4 percent for kanamycin, and 70.7 percent for amikacin among the 308 participants who were culture-positive for M. tuberculosis when phenotypic drug-susceptibility testing was used as the reference standard. For detection of phenotypic resistance the specificity of the assay was 93.4 percent or greater for all drugs except moxifloxacin at a critical concentration of 2.0 µg/mL. Using DNA sequencing as the reference standard, the sensitivities of the investigational assay for detecting mutations associated with resistance were 98.1, 95.8, 92.7, and 96.8 for isoniazid, fluoroquinolones, kanamycin, and amikacin; the specificity for all drugs was 99.6 percent or greater.

"This investigational assay accurately detected M. tuberculosis mutations associated with resistance to isoniazid, fluoroquinolones, and aminoglycosides and holds promise as a rapid point-of-care test to guide therapeutic decisions for patients with tuberculosis," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »